Poly-IC Preconditioning Protects against Cerebral and Renal Ischemia-Reperfusion Injury

Preconditioning induces ischemic tolerance, which confers robust protection against ischemic damage. We show marked protection with polyinosinic polycytidylic acid (poly-IC) preconditioning in three models of murine ischemia-reperfusion injury. Poly-IC preconditioning induced protection against isch...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cerebral blood flow and metabolism 2012-02, Vol.32 (2), p.242-247
Main Authors: Packard, Amy E B, Hedges, Jason C, Bahjat, Frances R, Stevens, Susan L, Conlin, Michael J, Salazar, Andres M, Stenzel-Poore, Mary P
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Brain - drug effects
Brain - physiopathology
Brain Ischemia - physiopathology
Brain Ischemia - prevention & control
Brief Communication
Cells, Cultured
Cytokines - blood
Interferon Inducers - therapeutic use
Ischemic Preconditioning - methods
Kidney - drug effects
Kidney - physiopathology
Kidney Diseases - physiopathology
Kidney Diseases - prevention & control
Male
Medical sciences
Mice
Mice, Inbred C57BL
Neurology
Neuropharmacology
Neuroprotective agent
Neuroprotective Agents - therapeutic use
Pharmacology. Drug treatments
Poly I-C - therapeutic use
Reperfusion Injury - physiopathology
Reperfusion Injury - prevention & control
Vascular diseases and vascular malformations of the nervous system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preconditioning induces ischemic tolerance, which confers robust protection against ischemic damage. We show marked protection with polyinosinic polycytidylic acid (poly-IC) preconditioning in three models of murine ischemia-reperfusion injury. Poly-IC preconditioning induced protection against ischemia modeled in vitro in brain cortical cells and in vivo in models of brain ischemia and renal ischemia. Further, unlike other Toll-like receptor (TLR) ligands, which generally induce significant inflammatory responses, poly-IC elicits only modest systemic inflammation. Results show that poly-IC is a new powerful prophylactic treatment that offers promise as a clinical therapeutic strategy to minimize damage in patient populations at risk of ischemic injury.
ISSN:0271-678X
1559-7016
DOI:10.1038/jcbfm.2011.160